Worldwide Clinical Trials Expands Clinical Pharmacology Unit
Upgrades include end-of-life equipment replacements and relocation.
Worldwide Clinical Trials has announced an expansion of the pharmacy at its Clinical Pharmacology Unit (CPU) in San Antonio, Texas, according to a company press release.1 In addition to equipment upgrades, expansion efforts focused on operational demand, workplace demand, and employee engagement with the overall goal of enhancing customer experience. Completed in January 2024, the expanded pharmacy provides customers with streamlined processes, as well as decreased timelines and costs.
“A common thread among our Worldwide team members is a passion to take care of our customers—we’re always looking for ways to improve our partnerships,” said Mike Mencer, executive vice president and general manager, early phase, Worldwide Clinical Trials in the press release. “As part of an ongoing $5 million upgrade to our CPU, this expansion aligns with our culture of quality and our dedication to continuous improvement and innovation to meet our customers’ growing needs as we work together to improve the lives of patients around the world.”
Worldwide’s CPU, a 200-bed, fit-for-purpose facility, has been in operation since 2005. Within the unit, studies are conducted in healthy volunteers, patients, and specialty populations. The CPU is conveniently located one hour from Worldwide’s Bioanalytical Center of Excellence, offering an approach that benefits customers through streamlined vendor management, consistent standards, technical expertise, and overall efficiencies such as sample transfer and rapid processing.
“Expanding our pharmacy in size enables us to expand in volume, providing additional opportunities and efficiencies for our customers,” said Lona Sheeran, senior vice president, clinical operations, early phase, Worldwide Clinical Trials in the press release. “We can now manufacture onsite, in real time, for Phase I studies per FDA guidance, allowing our customers the option to pivot on their dose while their study is ongoing. This service is unique and can save our customers thousands of dollars and months of time—a huge advantage in this fast-paced industry.”
Reference
- Worldwide Clinical Trials Expands Clinical Pharmacology Unit Pharmacy to Enhance Customer Experience; Adds Efficiencies and Decreases Timelines. News release. February 21, 2024. Accessed February 21, 2024. https://www.businesswire.com/news/home/20240221954891/en
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
